Condition: Hereditary Angioedema (HAE) · Sponsor: Pharvaris Netherlands B.V.
This is a Phase 3, multicenter, long-term, open-label study to evaluate the safety and efficacy of once-daily orally administered deucrictibant extended-release tablet for prophylaxis to prevent angioedema attacks in participants aged ≥12 years with Hereditary Angioedema
This description comes directly from the study's public registry record.
Pharvaris Clinical Team · 0031 712-036-410 · clinicaltrials@pharvaris.com
Always discuss trial participation with your own doctor first.
| Study Site | Birmingham, Alabama, United States | Recruiting |
| Study Site | Scottsdale, Arizona, United States | Recruiting |
| Study Site | Little Rock, Arkansas, United States | Recruiting |
| Study Site | San Diego, California, United States | Recruiting |
| Study Site | Santa Monica, California, United States | Recruiting |
| Study Site | Walnut Creek, California, United States | Recruiting |
| Study Site | Wheaton, Maryland, United States | Recruiting |
| Study Site | St Louis, Missouri, United States | Recruiting |
| Study Site | Las Vegas, Nevada, United States | Recruiting |
| Study Site | Hershey, Pennsylvania, United States | Recruiting |
| Study Site | Dallas, Texas, United States | Recruiting |
| Study Site | Milwaukee, Wisconsin, United States | Recruiting |
+ 50 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06679881